RGEN

<span> <p>WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3^rd at 10:40 a.m. CT.</p> <p>A live webcast of the conference presentation will be accessible through Repligen’s <a href="https://www.globenewswire.com/Tracker?data=DgAm15zrk5SafKW1d4Qi9d1UqJKzepl62pG88kbUJAGmdibS4WQQiuHN_-ZhaRo05uunGUijB3mJSwhWAOVa9z3cdUMCV-mJTkflGkqnCghmqvxsJdwJqXoAK9HlcxF-5p8Nq1rKg0sLIKsDxvd3lg==" rel="nofollow" target="_blank">Investor Relations</a> website at <a href="https://www.globenewswire.com/Tracker?data=zYv2Mqwfsf0nG0nsEO4gUeN-W4rUxXAK9HNAZHypGYH0qcW2rSaD7IUNTXnPmzL5MfdyBa3bAWrbITn1HUdZaEtSlWvMMRaw6kagG0VYzE4=" rel="nofollow" target="_blank">www.repligen.com</a>, and will be available for replay for a limited period of time following the event.</p> <p><strong>About Repligen Corporation </strong></p> <p>Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at <a href="https://www.globenewswire.com/Tracker?data=zYv2Mqwfsf0nG0nsEO4gUV08t97zKuoCX33-uAL0PylOf_svRZ7o1eOEKDra7V0FqEREtskx-EbyXdV1N_jrIryRF2-S64hTFRFuwYYU-pU=" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=lL4s6Wp0NiLpHR6tIDsWaT3HrAXt-qVo1fLS35RLjhoorpNQGs0T_9Yi1IrPFKqo7jc--Gd082U5njRFVwfE3p1Rao6UE-dEcpIpl2x8-zRnRl_ObB5KKOdT0R04y2EBGydCc93s2snYC4hYnf7p7g==" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p><strong>Repligen Contact: </strong><br />Jacob Johnson<br />VP, Investor Relations<br />781-419-0204<br /><a href="mailto:investors@repligen.com">investors@repligen.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNDk4NyM3NjE2NTIxIzIwMDUyMzg=" /> <br /><img alt="" src="https://ml.globenewswire.com/media/N2JlNjUyZGUtMTJmMS00ZDg2LWJiMGEtNGU5YjAzYzgwOGU4LTEwMTY4MTEtMjAyNi0wNS0yMi1lbg==/tiny/Repligen-Corporation.png" referrerpolicy="no-referrer-when-downgrade" /><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/967d43f6-7ffd-4ee0-8804-e3c12952402f"><img src="https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg" border="0" width="150" height="43" alt="Primary Logo" /></a></p> Source: Repligen Corporation</span>

<span> <p>WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed “<a href="https://www.globenewswire.com/Tracker?data=OQuBgGpKuc_fMMKUblN52aQfiLKI2ZGYVolTT_nrs6GXsftmpqdsHeYoe8mNxY68UYwpcNx6j5OdKZz_p10dNHMUsfNqrNPhIfJ6O4scSfb7816RfGa9gjnW0wOQ4dFJ85Zzxj5pAAdmH0ALRv2YwyQUzMOgek3APFfI-zTU-PSDMsBYkwTc7PTA3Uov26qfgZy_L8t6V0cvYiee6_EXxQ==" rel="nofollow" target="_blank">Driving Sustainable Growth Together</a>”, this report communicates the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB) Standards and the Task Force on Climate-related Financial Disclosures (TCFD), now part of the IFRS Sustainability Alliance.</p> <p>Olivier Loeillot, President and Chief Executive Officer at Repligen said, “Sustainability at Repligen is not a secondary effort—it is integral to how we grow, innovate, and support our customers. By investing in our people, strengthening governance, and acting responsibly, we are building a company that delivers lasting value for all stakeholders.”</p> <p>Dianne Heiler, Vice President of Sustainability & ESG and Global Head of Packaging Engineering at Repligen said, “Our company remains focused on transparency, rigor, and continuous improvement—investing in the foundations required to meet rising expectations with credibility, consistency, and integrity across our global operations.”</p> <p>Below are just a few of the 2025 Corporate Sustainability Report highlights across environmental, social, and governance topics. Report data is through year-end 2025 unless otherwise noted.</p> <p><strong>Advancing Impacts: Report Highlights</strong></p> <ul type="disc"><li>Maintained 100% renewable electricity across U.S. and European manufacturing operations.</li><li>Completed our first enterprise-level Double Materiality Assessment aligned with European Sustainability Reporting Standards (ESRS), enhancing prioritization of material topics and regulatory readiness.</li><li>Expanded the Board’s existing sustainability oversight by assigning regular oversight to the Audit Committee, reinforcing governance rigor, data integrity, and alignment with evolving stakeholder expectations.</li><li>Adopted new Human Rights and Sustainability and ESG policies, strengthening oversight and accountability.</li><li>Decreased year-over-year global water withdrawals by 14%.</li></ul> <p align="justify"><strong>About Repligen Corporation</strong><br />Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=825y7EB9VXKwlJWcDhXbj7a4gQmjouWnfIIMoOfkkm4psKXKW5sYPUCXB5n3nLZFHq19VgjLqnO2oqoiWGuJxPnkMYnFaWvDhwGmnfgEURE=" rel="nofollow" target="_blank">www.repli

<span> <p>WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT.</p> <p>A live webcast of the conference presentation will be accessible through Repligen’s <a href="https://www.globenewswire.com/Tracker?data=iD1fttkoGkxTytl9CiCy1bya4DKzsxjftfJb2H551wkNA1XmIBvONPG24TC_g7N1QPGPz-YBZuL21Sy42gJpqjhBcuwvWwszGhoBiPYlzN35bAy8OJBcXIO5k2T9c8e6qeEy7ggarWbnXUCubl8Qzg==" rel="nofollow" target="_blank">Investor Relations</a> website at <a href="https://www.globenewswire.com/Tracker?data=YH83uuwTIjUF-yXg96rGxp0cQ4UpDqGIMvCElVVoxD4SD80-ZyR-_gqIbTN85rx5XSaOg_4M1XqbknPxWcL5MytOC-uRkIbhmTHn9Kcmpt4=" rel="nofollow" target="_blank">www.repligen.com</a>, and will be available for replay for a limited period of time following the event.</p> <p><strong>About Repligen Corporation </strong></p> <p>Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at <a href="https://www.globenewswire.com/Tracker?data=YH83uuwTIjUF-yXg96rGxof2YLrJbriXoZ6-tjyGXKrhMrvd1y6du5TUbQlxRK6BRghZ_n29c9lKM9vlYlbvPANl4XPhyDMaDOtaGdLt3h8=" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=_pF-1dMSj70XaoG0Pus_khrvAQ98PYe0sFAPdYKfVp2LTaveh_YXHUkpkMIuclLgLP27n7xGqIc4v8SIZ_H-x44gmpcwTN7Kiuy32o3vL9TDhy4rVXr3_EQa-r6a8qf2ZDO38fvX5ivBsfcm5UWeHw==" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p><strong>Repligen Contact: </strong><br />Jacob Johnson<br />VP, Investor Relations<br />781-419-0204<br /><a href="mailto:investors@repligen.com">investors@repligen.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNDk5NyM3NTg4ODM0IzIwMDUyMzg=" /> <br /><img alt="" src="https://ml.globenewswire.com/media/MzgzNDdiMjktYTdmZi00YTc5LTgyYTAtYjlmZDI5NGI2NzA4LTEwMTY4MTEtMjAyNi0wNS0wNy1lbg==/tiny/Repligen-Corporation.png" referrerpolicy="no-referrer-when-downgrade" /><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/967d43f6-7ffd-4ee0-8804-e3c12952402f"><img src="https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg" border="0" width="150" height="43" alt="Primary Logo" /></a></p> Source: Repligen Corporation</span>

<span> <ul type="disc"> <li style="margin-top:6pt;"> <em>First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic</em> </li> <li style="margin-top:6pt;"> <em>GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year</em> </li> <li style="margin-top:6pt;"> <em>Reiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05</em> <br /> </li> </ul> <p>WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026.</p> <p>Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We delivered a very strong start to the year, achieving 11% organic revenue growth and 160 basis points of adjusted operating margin expansion, exceeding expectations as our team executed well across the business. Combined with recent order trends, these results reinforce our confidence in our full-year revenue outlook.”</p> <p>“We also continue to make meaningful progress on our strategic priorities. We launched a Transformation Office initiative and divested a non-core filtration business as we accelerate our focus on profitable growth. In addition, we entered into a new partnership in China, which represents an important step in advancing our APAC strategy. We remain committed to disciplined, intentional investment—expanding our commercial capabilities and optimizing our infrastructure to support scalable, sustainable growth in the years ahead.”</p> <p><strong>BUSINESS HIGHLIGHTS</strong></p> <ul type="disc"><li style="margin-top:6pt;"><strong>China Partnership. </strong>In April, we signed a partnership agreement in China, which outlines an OEM relationship that will increase our competitiveness and access to local manufacturing.</li><li style="margin-top:6pt;"><strong>Launched Transformation Office. </strong>We recently launched a Transformation Office, focused on accelerating our fit-for-growth journey and our commitment to margin expansion. This includes efforts around site rationalization, product line margin optimization, and accelerating IT and AI investments, among other areas.</li><li style="margin-top:6pt;"><strong>Divested Polymem.</strong> As part of our transformation efforts, we divested Polymem on March 30^th. The business generated $7 million of revenue and an operating loss in 2025. FY26 guidance now reflects this divestiture.<br /></li></ul> <p><strong>FINANCIAL PERFORMANCE </strong></p> <p>Q1 2026 Financial Performance (compared to prior year periods except as noted)</p> <p><em>All adjusted figures are non-GAAP and, except for earnings per share (“EPS”), are rounded to the nearest million, and are reconciled in the tables included later in this press release.</em></p> <ul type="disc"><li style="margin-top:8pt;">Q1 reported revenue was $194 million, compared to $169 million, an increase of 15% as reported and 11% organic.</li><li style="margin-top:8pt;"><strong>GAAP Results</strong>. Q1 income from operations was $16 million, compared to $7 million. Q1 EPS was $0.15 on a fully diluted basis, compared to $0.10.</li><li style="margin-top:8pt;"><strong>Adjusted Results. </strong>Q1 adjusted income from operations was $30 million, compared to $23 million. Q1 adjusted EPS was $0.48 on a fully diluted basis, compared to $0.39.<br /></li></ul> <p><strong>MARGIN SUMMARY</strong></p> <table align="center" style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:74%; width:74%; min-width:74%;;vertical-align: bottom ; "><strong>GAAP Margins</strong></td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom

<span>Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET<p align="justify">WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026.</p> <p>The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the <a href="https://www.globenewswire.com/Tracker?data=iZO5EbPa-ThKmmblMcz4qCxAZN8q9ln3Vk4lIXON5IJgTNGeQd--iVxv2Fdn0Eg1BrbKVynUl1lIv8o69PeNZS6U5hO_c1SoKDOkW8y8tplTBdYTxzSQTMEk1KavAY5fTrf7vNkOQb8rOz_Qu07BVSn4YqCjNlgXDAZHp1lt1l-L2y71mAPU7r3bCr--ap91letwaa0EXMQkmAI26oLqkydd7gcKYF7dPs98SPYgL1ZLpwiDserc-KneG0rZiKEzVjdUVEMaHekA807l6uoOy4eDvK0Y7GVOzlhssmZ0Y3Z_Wi0alWT6YIK0YHq3lqxGxauvKwdchtU7d9cffJwOijLN6BqwTLl9NIBcFUE_egI=" rel="nofollow" target="_blank">Investor Relations</a> section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the <a href="https://www.globenewswire.com/Tracker?data=iZO5EbPa-ThKmmblMcz4qK9MQvbML1FL5UzKN-cfFH43mD2lt81vITIhZqv_5R0Nei2BrTnDQQaIxgcTLHKot_AhaCNpFpy65wD4KoBQyLmfr3w87ksfZNV5YtCjkGMeiCpuMpd5rmYbtZM_LuFu3B2WL00otGHOq4ctvfFBkA-fLXBb7-GhGhJ1QA_B8MgnBo0Kz8fb8xJOyB75Ut68fhIL_vBRQ5Hjaz2PFJr0BYwNj2ASnhhuKesjmgrieOXK44W0uZs2mhYi6lOKNBKRpUOtLMGglkGjFNkW0c4RfJdqMAEPAqKc1la87f5o3qchGxk2gzsSqu74xiO0ZAMI_YRS19785XGfIsL0tgsdLZk=" rel="nofollow" target="_blank">Investor Relations</a> section of the Company’s website.</p> <p align="justify"><strong>About Repligen Corporation<br /></strong>Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at <a href="https://www.globenewswire.com/Tracker?data=M59HlSrZL_RK3_szrQKc22CrINOTQMy-K98_AM1IS9CN_VBMhzz7Ecssc-_tD37QLI85UkW_IisC_Db_Ag3bfQq3kTHJiDo83yk55LLyQZoqwK-Io7Y-cYd9iPPuvys1u7YnfvYH5jUtREuHtdWsWNK2lRmMqU3JhIyqSY_lqxaQvxGiTKcAmjEc8FnXfFNMUkksdHTlZxeYeVqQFa5i-UO0E5hh7Pa9HKc-3WmeDJhLFZbPo6qABGUNitInV890TXtY7VHx5tzltEdBPBwhyw==" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=peNBl_XyXwZdujrmxj7vowHIAbU9pPQeCFeg6qr4QeZDr_3tTt5IfUfiU5hPg2_Oz9SAaDEL_W5ELOqpF4P6yieOlFPNYo4cvZdnG0_5Ap3rzf2jVBCT_S8u8U-ZPomFE23G5yJ0Fcji1fDxgdJbu-ig61dXHTVfCSmEhxnpvGoI7t6cdz0SX-SQ9BiC2R1hqsPRwVu0878ZFY7T2JS4ipDpXRmBhQWFGkpUErHS9PACQOPwItqI5khWmS16eF8FMo9GlxiaaQ1AEKx6Pif2QQ==" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p align="justify"><em>This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements a

<span> <p>WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen’s innovative bioprocessing solutions.</p> <p>The Breda RTIC is Repligen’s third global training and innovation center, joining existing locations in Waltham, Massachusetts and Tokyo, Japan. The Breda opening event, held on April 15th, welcomed key biopharma and CDMO customers and highlighted Repligen’s continued investment in customer proximity and global support capabilities.</p> <p>Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We are excited to open our third RTIC in Breda. The center provides a site for workshops and hands-on training for our technical teams and customers, while also highlighting our increasingly broad and diversified portfolio and end-to-end bioprocessing capabilities. Alongside recent investments in Asia Pacific and continued investment in the U.S., this opening underscores our commitment to serving customers globally.”</p> <p>The Breda RTIC enables the functional display of all Repligen bioprocessing technologies; a complete collection from across the company’s global manufacturing sites. Upstream intensification technologies on display include XCell® ATF and KrosFlo® TFDF® devices and controllers. Downstream offerings include OPUS® pre‑packed chromatography columns, Spectrum® hollow fiber filters, TangenX® flat sheet cassettes, and affinity resins. There will be a number of systems on permanent display, including the KRM™ 10 Chromatography System, KrosFlo® RS 10 and RS30 RPM™ TFF Systems, and KrosFlo® KR2i RPM™ TFF System, highlighting the Company’s growing capital equipment offerings. Also on display will be the PATsmart™ Upstream and Downstream Analytical Solutions and Fluid Management products including ProConnex® MixOne RG-X and ProConnex® MixOne CB-X systems and flow paths, non-metallic equipment and a number of valve, clamp and tubing technologies.</p> <p align="justify"><strong>About Repligen Corporation<br /></strong>Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at <a href="https://www.globenewswire.com/Tracker?data=sIfZCe-PRLAddgjDiGlUAbChuuiVikpZgDBomRb1LV1-hS-1qbQYkE-2Dgks1jYd5j9zCAy97Jx7bBa-_HBi1sB_zFJIQHfWLcya1OGELe4=" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=Oa-fLu_p9cfK5J_nfCz-omU-RICGICKtv8LOCSZy-0Ja71Huel8Cp7HsCVAvxubbt_g5aSMYIXN_gAgy3P2d5R19EE0uqDwTq5HvJS9kJAD7VgVPy4IKNHD-L3FMrW_h" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p align="justify"><em>This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limi

<span> <p>WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three upcoming investor conferences.</p> <ul type="disc"><li style="margin-top:4pt;">The Leerink Global Healthcare Conference, being held March 8 – 11 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 11:20 a.m. ET on Tuesday, March 10, 2026.</li><li style="margin-top:4pt;">The Barclays 28th Annual Global Healthcare Conference, being held March 10 – 12 in Miami. Jason Garland, Chief Financial Officer, will participate in an analyst led discussion at 10:30 a.m. ET on Wednesday, March 11, 2026.</li><li style="margin-top:4pt;">The 2026 KeyBanc Virtual Healthcare Forum, being held March 17 – 18. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 2:15 p.m. ET on Wednesday, March 18, 2026.</li></ul> <p>A live webcast of the Leerink and KeyBanc presentations will be accessible through Repligen’s <a href="https://www.globenewswire.com/Tracker?data=YrF0LYuX--hvd7Ywp8Q4ALZkYBKFfr5k66-CeUE1jRPWMwBqgmxqMBu3TuWIUzy_jC-XYU1P7U5W2H1_yojHMkR5nHZrVs8Et3Bnh9wBaH5T1hvVt0V5NtwuMzC1nCQLBufNlRk3hkQYhg3tHVhmPg==" rel="nofollow" target="_blank">Investor Relations</a> website at <a href="https://www.globenewswire.com/Tracker?data=9zYiRRQpgM6uAF2BBAYq7cMI4Nz-WJ0dLUikqKj_uhCckabJ-DSKnvc-zVqwUm0RD6NmqBKwe2GLcW3zSqTq76KZiVn4SXt8PefYOIiZAkE=" rel="nofollow" target="_blank">www.repligen.com</a>, and will be available for replay for a limited period of time following the events.</p> <p align="justify"><strong>About Repligen Corporation</strong><br />Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at <a href="https://www.globenewswire.com/Tracker?data=9zYiRRQpgM6uAF2BBAYq7TYr_HtVfhGT5TK-cB_oHJb305eMfCoMnSlExR1km6zdPRLl4_DQjzDHH2kjsxrvhk9pe1F9MWQ2XmYvBqZUvS4=" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=4BgmEEn5eIiBpHLpu1HV8DoToUCOpSzrTPYH1JiEHDNifPuFiH6etXWC4tviLqhFZxSrzlN-zTDJYv6T_ZsK_YgEtZMzXzXfwF40G7BHuAvRwjE0bO3XiniqFcxeoGCK" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p><strong>Repligen Contact: </strong><br />Jacob Johnson<br />VP, Investor Relations<br />781-419-0204<br /><a href="mailto:investors@repligen.com">investors@repligen.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NjA5NSM3NDY4MzU5IzIwMDUyMzg=" /> <br /><img alt="" src="https://ml.globenewswire.com/media/OWNmZGZlNWUtMTdhMS00MTViLWJkMDItMDU2ZjBhMWM2Yjc2LTEwMTY4MTEtMjAyNi0wMy0wNS1lbg==/tiny/Repligen-Corporation.png" referrerpolicy="no-referrer-when-downgrade" /><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/967d43f6-7ffd-4ee0-8804-e3c12952402f"><img src="https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg" border="0" width="150" height="43" alt="Primary Logo" /></a></p> Source: Repligen Corporation</span>

<span> <ul> <li> <em>Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter</em> </li> <li style="margin-top:6pt;"> <em>Full year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVID</em> </li> <li style="margin-top:6pt;"> <em>Full year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint</em> <br /> </li> </ul> <p>WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026.</p> <p>Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had a great finish to 2025 with 14% organic growth in the quarter led by Analytics and Proteins.&nbsp;As a result, we exceeded the high end of our October revenue and adjusted operating income guidance. We are thrilled by our strong performance in 2025 with 16% organic non-COVID growth driven by traction across our differentiated portfolio, while continuing to expand margins.</p> <p>“As we turn the page to 2026, we are excited about our product portfolio, the team we've built, and the strategy we are executing. We are investing with intention: expanding our commercial presence and scaling our operations for greater agility. We remain focused on innovation that enables customers to accelerate development and improve yields. Our initial 2026 guidance calls for 10% - 14% revenue growth, which we believe is an appropriate starting point for the year and includes a two-point gene therapy headwind. In addition, we expect 150 bps of adjusted operating margin expansion at the midpoint.”</p> <p><strong>Q4 2025 BUSINESS HIGHLIGHTS</strong></p> <ul type="disc"><li style="margin-top:6pt;"><strong>Executed on All 2025 Strategic Priorities</strong>. <ul type="circle"><li style="margin-top:6pt;">Delivered 14% organic growth in FY25, which surpassed the high end of our initial guidance range and meaningfully outpaced market growth.</li><li style="margin-top:6pt;">Increased FY adjusted operating margins by 90 bps or 240 bps excluding the impact of M&A and foreign exchange, while making key investments across our portfolio and becoming more fit for growth.</li><li style="margin-top:6pt;">Expanded our Analytics portfolio via M&A and launched multiple new products across our Analytics, Filtration, and Proteins franchises.</li></ul> </li><li style="margin-top:6pt;"><strong>Proteins Launch</strong>. Launched three new high® performance chromatography resins: AVIPure HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the Company’s growing proteins portfolio and reinforcing our commitment to innovation in next-generation bioprocessing.</li><li style="margin-top:6pt;"><strong>APAC Investments</strong>. In the fourth quarter, we opened a new office in Singapore and expanded our footprint in Japan. This builds on our growing APAC presence as we continue to invest in the region to support future growth.</li></ul> <p><strong>FINANCIAL PERFORMANCE </strong></p> <p>Q4 and Full Year 2025 Financial Performance (compared to prior year periods except as noted)</p> <p><em>All adjusted figures are non-GAAP and, except for earnings per share, are rounded to the nearest million, and are reconciled in the tables included later in this press release.</em></p> <ul type="disc"><li style="margin-top:8pt;">Q4 reported revenue was $198 million, compared to $168 million, an increase of 18% as reported and 14% organic, bringing our full year 20

<span>Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET<p align="left">WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025.</p> <p>The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the <a href="https://www.globenewswire.com/Tracker?data=uHHlRnkcSIBqv0aE9ClpU8XmYldWFD5E2gDO4KfNomslyZaBuEiWQ-N_U44zlpo1azkzRrPytSfmkvgeU9ESSiDaBf4esNlipLmoVede-Z5kyKeBf0VFVVd-ZH1LabUKjCGmXRgKNGmLGWFIF_jNQhiMkBHRwQ0r6tOjM1N5sZIg1t_ZZOK0euOYF7_YGPvldZiKA32g7PojxMNCARAoBBBLw-m3lvNXW_PxpWjjStwpyv76bdh6AILbD8ugZvDHHEXAhOJH9O5NbB_fNm_CxDgh1By6ykl0aGbm39To2yQFeLihc5BOKPtiY5iwhkjKWI9R733nXw2YHmTyepfk58WGcwtA9gw2rOb7JR8mY9k=" rel="nofollow" target="_blank">Investor Relations</a> section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. You can access the replay on the <a href="https://www.globenewswire.com/Tracker?data=uHHlRnkcSIBqv0aE9ClpU_mdoM1aL7JmSOTBVcdI6vYTnuSMQPk3BJCzrM44PNSQnMi5rb5dqJMPWZJXkDlbSr4DRZC0DRiEzKaVV8lS1zbi-zWWmrxel4HkYdOyo9SNn83bLCR4FD5iCrfQo6TN-5ZSo1v3Z6jyvZZRTqKeYmGI4sQFm8eXrxSYJBLvPZ1gtLirE9h1qmdpZOBBGYYQKKuEavViXIHa7jiVqF2LFXgBWyAUeOYx6MMwtHdc4Oh9tHAnuS39PnNlRZVBZVe3MZlrRw0REZwqk4msgcKsH67IDfGf3nH1CBA-poXYCuigXjfQe4BMJwBO2R9_V1q8tOY4yBtoOAN4AgUbnEFaAkQ=" rel="nofollow" target="_blank">Investor Relations</a> section of Company’s website.</p> <p><strong>About Repligen Corporation</strong></p> <p align="justify">Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at <a href="https://www.globenewswire.com/Tracker?data=ruTiE2mE2iBoY6b3-LaswfUDXGZC8n0vK0MrrbT6CM-0MxH6TFEJxWBtcBDJ-dwZVqbZe5-knVuefriXeWC4Hk-NKYBZwqZKHu4aLX0twAemvZXBeIZnFC4q8FVJJYrVHuc04Uv1TxyT0tDsT1Mq3_xah-FVOLjnMRFt3uCoUE-0nmSPmcbmR5pYOL6EnrxIKjGSSQNiL6-GjPiIa5HS6pLSsfnvAKX52vI4srjDgh3OrpZ1vuwz6oAXMg7ou6GAX_OctaZCvlmjUMszCZlkUw==" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=tyCej76AyhUsRpo9I7vED5o2wYyN0f6nD_2PQuqlnGi2LU5qZiV1vSmayu7FS7GmTj1Qk8EVOtf_PnaFNeWPlhcrDpZ6HC_wSjpQBgs9hckNMs3UgSQyJrKdalxM6PdCxgLCSCb5LbFOwiphEP3TQxLsg8Uhny2tUqodcqqdDRi2mzCpcYM6dg1WiFKIkTRTmIwtU_L2bfpybjOTj6gOrUb-o5D0cf0Kss3Sb7KTozNYTQsEtMJ9NozPoHDI2LJ_rotoixe2NcXeWKQTN5NJng==" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p align="justify"><em>This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, const

<span> <p>WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated¹, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.</p> <p>“On behalf of Repligen, I want to thank Tony for over a decade of service to the Company, during which he expanded our unique and diversified portfolio of innovative products,” said Olivier Loeillot, Repligen President and CEO. “He left a strong foundation for us to build upon, and with Martin assuming the role of Chair of the Board, we are well-positioned for success. Martin’s deep expertise and strong leadership in bioprocessing and biopharma makes him exceptionally qualified to lead our Board.”</p> <p>Dr. Martin D. Madaus added, “On behalf of the Board of Directors, our shareholders, employees, and other stakeholders, I want to commend Tony on his impressive tenure at Repligen. I am honored to be elected as Chair of the Repligen Board and look forward to guiding Repligen towards new heights.”</p> <p>Tony Hunt said, “After more than a decade of leadership, I leave this Company immensely proud of the business we have created together. One that is rooted in clear strategy, disciplined execution and outstanding people. It has been a privilege and an honor to work alongside such a committed team, and I leave knowing the Company is in very capable hands. I am confident that Olivier and Martin will build on the success we have enjoyed and lead Repligen to a new phase of growth.”</p> <p>Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.</p> <p><strong>About Repligen Corporation</strong></p> <p align="justify">Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are <em>“inspiring advances in bioprocessing”</em> for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at <a href="https://www.globenewswire.com/Tracker?data=mJ70pvIP3n0PpvwgjbGsvLLLqENb-D6sComStwazHZYyx6H5OExf2QxRTu8mVHtj0TR0QVtn5x0QVjAwP2KLKs6C8zzH7oHHxRZ6s9JKwfc=" rel="nofollow" target="_blank">www.repligen.com</a>, and follow us on <a href="https://www.globenewswire.com/Tracker?data=OwKHPEDPgpPpQeQSrAN_6o9lYHA-hPOOdBt3rS0paiJeyokKD6HC4T09qWssYiKvwp4sgUnZOiDZFL_BB3GLjoNycfGWDV6ip8S6l7BoVovQNYUEmY1_qCwFTQfMpkC_" rel="nofollow" target="_blank">LinkedIn</a>.</p> <p align="justify"><em>This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, state